POS1254 REDUCED HEALTH-RELATED QUALITY OF LIFE USING PROMIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL ANALYSIS FROM THE INTERNATIONAL COVAD-2 E-SURVEY
Authors: K. Yomono, Y. Li, V. Maroufy, N. Ravichandran, A. Yoshida, K. Jagtap, T. Velikova, P. Sen, L. Cavagna, V. Agarwal, J. Knitza, A. Makol, D. Dzifa, C. E. Toro Gutierrez, T. Chatterjee, A. Patel, R. Aggarwal, L. Gupta, M. Kuwana, V. Agarwal
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The second COVID-19 vaccination in autoimmune disease (COVAD-2) study [1] is an international, multicentre, self-reported e-survey designed to evaluate several facets covering COVID-19 infection and vaccination as well as validated patient-reported outcome measures (PROMs) in a variety of autoimmune diseases (AIDs), including systemic sclerosis (SSc). Detailed assessment of the health-related quality of life (HRQOL) and its drivers in patients with SSc is lacking. <h3>Objectives</h3> To assess physical and mental health in a global cohort of SSc patients in comparison with non-SSc autoimmune inflammatory rheumatic diseases (AIRDs), non-rheumatic AIDs (NRAIDs), and those without AIDs (controls) using Patient-Reported Outcome Measurement Information System (PROMIS) global health data from the COVAD-2 survey. <h3>Methods</h3> The COVAD-2 database was used to extract demographics, AID diagnosis, comorbidities, disease activity, current therapies, and PROMs. PROMIS global physical health (GPH), global mental health (GMH) scores, PROMIS physical function short form-10a (PROMIS PF-10a), pain visual analogue scale (VAS), and PROMIS Fatigue-4a scores were compared between SSc, non-SSc AIRDs, NRAIDs, and controls. Outcomes were also compared between diffuse cutaneous SSc (dcSSc) vs limited cutaneous SSc (lcSSc). Multivariable regression analysis was performed to identify factors influencing GPH and GMH scores in SSc. <h3>Results</h3> A total of 10,502 complete responses from 276 SSc, 6006 non-SSc AIRDs, 545 NRAIDs, and 3675 controls as of May 2022 were included in the analysis. Respondents with SSc were older [SSc <i>vs.</i> non-SSc AIRDs <i>vs</i>. NRAIDs <i>vs</i>. controls: 55 (14) <i>vs.</i> 51 (15) <i>vs</i>. 45 (14) <i>vs</i>. 40 (14) years old, mean (SD), p &lt; 0.001]. Among patients with SSc, 129 (47%) had dcSSc and 147 (53%) had lcSSc. SSc patients reported a significantly higher prevalence of ILD [SSc <i>vs.</i> non-SSc AIRDs <i>vs</i>. NRAIDs <i>vs</i>. controls: 30.4% <i>vs.</i> 5.5% <i>vs</i>. 1.5% <i>vs</i>. 0.2%, p &lt; 0.001], and treatment with MMF [SSc <i>vs.</i> non-SSc AIRDs <i>vs</i>. NRAIDs <i>vs</i>. controls: 26.4% <i>vs.</i> 9.5% <i>vs</i>. 1.1% <i>vs</i>. 0%, p &lt; 0.001]. Patients with SSc had lower GPH and PROMIS PF-10a scores [SSc <i>vs.</i> non-SSc AIRDs <i>vs</i>. NRAIDs <i>vs</i>. controls: 13 (11–15) <i>vs.</i> 13 (11–15) <i>vs</i>. 15 (13–17) <i>vs</i>. 17 (15–18), median (IQR), p &lt; 0.001; 39 (33–46) <i>vs.</i> 39 (32–45) <i>vs</i>. 47 (40–50) <i>vs</i>. 49 (45–50), p &lt; 0.001, respectively] and higher Pain VAS and PROMIS Fatigue-4a scores compared to those with NRAIDs or controls [SSc <i>vs.</i> non-SSc AIRDs <i>vs</i>. NRAIDs <i>vs</i>. controls: 3 (2–5) <i>vs.</i> 3 (1–6) <i>vs</i>. 2 (0–4) <i>vs</i>. 0 (0–2), p &lt; 0.001; 11 (8–14) <i>vs.</i> 11 (8–14) <i>vs</i>. 9 (7–13) <i>vs</i>. 7 (4–10), p &lt; 0.001, respectively]. Patients with AIDs including SSc had lower GMH scores compared to controls [SSc <i>vs.</i> non-SSc AIRDs <i>vs</i>. NRAIDs <i>vs</i>. controls: 12.5 (10–15) <i>vs.</i> 13 (10–15) <i>vs</i>. 13 (11–16) <i>vs</i>. 15 (13–17), p &lt; 0.001]. Among SSc patients, GPH, GMH, and PROMIS PF-10a scores were lower in dcSSc compared to lcSSc [dcSSc <i>vs.</i> lcSSc: 12 (10–14) <i>vs.</i> 14 (11–15), p &lt; 0.001; 12 (10-14) vs. 13 (10-15), p&lt;0.001; 38 (30–43) <i>vs.</i> 41 (34–47), p &lt; 0.001, respectively]. Pain VAS and PROMIS Fatigue-4a scores were higher in dcSSc compared to lcSSc [4 (2–6) <i>vs.</i> 3 (1–5), p &lt; 0.001; 12 (8–15) <i>vs.</i> 9 (8–13), p &lt; 0.001, respectively]. The independent factors for lower GPH scores in SSc were older age, Asian ethnicity, glucocorticoid use, and higher pain and fatigue scales, while mental health disorders and higher pain and fatigue scales were independently associated with lower GMH scores. <h3>Conclusion</h3> In a global cohort, patient-reported physical and mental health were significantly worse in patients with SSc in comparison to those with non-SSc AIDs and without AIDs. Our findings support the critical need for more attention to patient's subjective experiences including pain and fatigue to improve the HRQOL in patients with SSc. <h3>Reference</h3> [1]Fazal ZZ, Sen P, Joshi M, et al. COVAD survey 2 long-term outcomes: unmet need and protocol. <i>Rheumatol Int</i>. 2022; 42: 2151–58. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Keina Yomono: None declared, Yuan Li: None declared, Vahed Maroufy: None declared, Naveen Ravichandran: None declared, Akira Yoshida: None declared, Kshitij Jagtap: None declared, Tsvetelina Velikova Speakers bureau: Pfizer and AstraZeneca, Parikshit Sen: None declared, Lorenzo Cavagna: None declared, Vishwesh Agarwal: None declared, Johannes Knitza: None declared, Ashima Makol: None declared, Dey Dzifa: None declared, Carlos Enrique Toro Gutierrez: None declared, Tulika Chatterjee: None declared, Aarat Patel: None declared, Rohit Aggarwal Consultant of: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Kyverna Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therepeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, and CabalettaBio, Grant/research support from: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Kyverna Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therepeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, and CabalettaBio, Latika Gupta: None declared, Masataka Kuwana Speakers bureau: Abbvie, Asahi-Kasei, Astellas, Boehringer-Ingelheim, Chugai, Eisai, MBL, Mochida, Nippon Shinyaku, Ono Pharmaceuticals, Tanabe-Mitsubishi, Consultant of: Astra Zeneka, Boehringer-Ingelheim, Chugai, Corbus, GSK, Horizon, Tanabe-Mitsubishi, Grant/research support from: Boehringer-Ingelheim, Vikas Agarwal: None declared.